Vericel Corp (VCEL) stock
Close on Nov 11, 2026Market cap $3.04BP/E 100.8Yield –
Vericel Corp grew revenue 25.3% to $324.17M over the twelve months to Sep 30, 2026. Operating income rose 279.4% to $26.97M, moving the operating margin from 2.7% to 8.3%. Free cash flow was $57.89M, up 184.1% from a year earlier. At the latest close the market valued the company at $3.04B, 100.8 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $3.04B
- P/E ratio
- 100.8
- Price to sales
- 9.39
- Price to book
- 7.92
- Dividend yield
- –
- Free cash flow yield
- 1.90%
Fundamentals
- Revenue
- $324.17M
- Net income
- $33.31M
- EPS, diluted
- $0.59
- Free cash flow
- $57.89M
- Book value per share
- $7.25
- Diluted shares
- 53M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $59.03
- Open
- $58.42
- Day's range
- $57.76 – $59.75
- Volume
- 809,563
- Average volume (20 days)
- 900,707
- Index membership
- S&P SmallCap 600 (since May 2021), Russell 2000, Russell 3000
- Beta (5 years)
- 1.05
- 52-week range
- $28.95 – $59.75
- RSI (14 days)
- 82.6
- Volatility (1 year)
- 45.1%
- Relative volume
- 1.37×
- WACC
- 10.1%
On 1 of our idea list: Breakout quarter
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | VCEL | S&P 500 | Difference | VCEL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +48.3% | -2.4% | +50.7 pts | ||
| 3 months | +34.0% | -1.2% | +35.2 pts | ||
| Year to date | +65.1% | +12.3% | +52.8 pts | ||
| 1 year | +44.8% | +12.4% | +32.4 pts | ||
| 3 years | +75.3% | +78.8% | −3.5 pts | +20.6% | +21.4% |
| 5 years | +39.6% | +75.2% | −35.5 pts | +6.9% | +11.9% |
| 10 years | +2542.2% | +311.1% | +2231.1 pts | +38.7% | +15.2% |
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Vericel filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Vericel
Biological Products, (No Diagnostic Substances)
Vericel Corporation develops and commercializes advanced cell therapies and specialty biologics focused on the sports medicine and severe burn care markets. Its commercial product portfolio features MACI, an autologous cellular scaffold implant and related surgical instruments used by orthopedic surgeons to repair knee cartilage defects in adults. In severe burn care, the company provides Epicel, an autograft skin replacement device for extensive deep-dermal or full-thickness burns, and NexoBrid, an enzymatically active topical biologic for eschar removal in pediatric and adult patients. Vericel markets these therapies across the United States to orthopedic surgeons, hospitals, and specialized burn treatment centers.
Company profile, executives and historyVericel stock: common questions
What is Vericel's stock price?
VCEL closed at $59.45 on Nov 11, 2026, up 0.71% on the day. Over the past 52 weeks it traded between $28.95 and $59.75.
What is Vericel's market cap?
Vericel was worth $3.04B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is VCEL's P/E ratio?
VCEL trades at 100.8 times earnings, based on diluted earnings per share of $0.59 over the twelve months to Sep 30, 2026.
How much revenue does Vericel make?
Vericel reported revenue of $324.17M for the twelve months to Sep 30, 2026, up 25.3% from a year earlier.
Does Vericel pay a dividend?
No. Vericel has not paid a cash dividend over the last twelve months.
When does Vericel report earnings next?
Vericel is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has VCEL stock performed over the past year?
Including dividends, VCEL returned +44.8% over the past year, against +12.4% for the S&P 500.
How many VCEL shares are sold short?
5M shares were sold short at the latest FINRA report, 10.61% of the float, or 9.8 days of average trading volume.
Who are Vericel's competitors?
Companies most similar to Vericel by business, industry and size include ORGO, IOVA, MESO, KRYS, ADMA.
See a number that looks wrong?